Tag Archives: Biotech Patenting

PTAB, IPRs and Uncertainty in the Patent System

shutterstock_26191726

The topic of inter partes reviews (IPRs) has dominated conversation in patent circles for the last several years (see our archive for some of our past articles on the subject). As uncertainty grows in the biopharma community about IPR procedures and the future of innovation, BIO will make IPRs a major topic of discussion at our upcoming IP and Diagnostics Symposium (BIO IPDX) as well as BIO’s IP Counsels Committee Meeting in November. An administrative Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO and University Organizations offer Support of STRONG Patents Act

shutterstock_26191726

On March 4, 2015, Senator Chris Coons (D-DE) introduced a new bill, The STRONG Patents Act of 2015. Sponsored alongside Sen. Richard Durbin (D-IL) and Sen. Mazie Hirono (D-HI), the bill is offered as a complement to House Judiciary Committee Chairman Goodlatte’s (R-VA) Innovation Act, which many in the biotech sector see as an imbalanced bill. The STRONG Patents Act of 2015 would target the abusive practices of patent trolls in a narrowly tailored setting, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

BIO IPCC Spring Conference Program Announced

IPCC Logo

BIO’s 2015 IP Counsels Committee Spring Conference & Meeting will be held April 15-17 in St. Louis, Missouri, at the Four Seasons St. Louis Hotel. The biannual conference offers timely, relevant educational sessions on the latest issues in the biotech IP sector, informal networking events designed to promote discussion and foster relationships among industry colleagues, and practical tips for attendees to use the next day. Attendees will hear from the foremost experts in biotech IP Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

BIO Deputy General Counsel Remarks on Revised Eligibility Guidance

Supreme Court

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property recently spoke at the U.S. Patent and Trademark Office’s public forum on patent-eligible subject matter. The forum was a chance for the Office to receive public feedback regarding the most recently revised Eligibility Guidance for determining subject matter under 35 U.S.C. 1010. Biotechnology advocates are concerned that PTO examiners have interpreted recent decisions by the U.S. Supreme Court, including those in Alice Corp, Myriad, and Mayo Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

BIO Coalition Submits Patent Reform Letter to Congress

medical_research

BIO, alongside a coalition of patent holders and inventors, submitted a letter to the chairmen and ranking members of the House and Senate Judiciary Committees on December 10 regarding potential changes to the patent system. The coalition thanked members of the committee for their work to develop reforms which would prevent harmful patent enforcement practices, and once again reiterated their opposition to any legislation that would weaken the overall patent system. They also asked that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,